Xenon Pharmaceuticals EBIT

Xenon Pharmaceuticals (XENE) currently reports a EBIT of $-420M as of June 2026. That compares with $-320M in the prior-year period — down 33.5% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Xenon Pharmaceuticals's EBIT history and peer comparisons.

Xenon Pharmaceuticals's EBIT decreased from $-320M to $-420M — a 33.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Xenon Pharmaceuticals's EBIT of $-420M is lower than the Healthcare sector average of $23B. That is roughly 101.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Xenon Pharmaceuticals reported $-420M in EBIT as of June 2026. That compares with $-320M in the prior-year period — down 33.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-420M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Xenon Pharmaceuticals, and consider following XENE for alerts when major investors trade the stock.